Drugs Made In America Acquisition Corp(DMAA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:00 PM ET (Korea 9/12 05:00)
Full metrics table
| Index | - | P/E | 58.06 | EPS (ttm) | 0.19 | Insider Own | 23.57% | Shs Outstand | 24.3M | Perf Week | 0.47% |
| Market Cap | 0.26B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 18.6M | Perf Month | 0.84% |
| Enterprise Value | 0.26B | PEG | - | EPS next Q | - | Inst Own | 49.3% | Short Float | 0.43% | Perf Quarter | 1.79% |
| Income | 0.01B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 1.94 | Perf Half Y | 3.15% |
| Sales | 0.00B | P/B | 1.9 | EPS next 5Y | - | ROA | 3.18% | Short Interest | 0.08M | Perf YTD | 4.1% |
| Book/sh | 5.67 | P/C | 13109.5 | EPS past 3/5Y | - | ROE | 3.33% | 52W High | 0% ($10.80) | Perf Year | 5.37% |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | 4.42% | 52W Low | 5.57% ($10.23) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 89.22% | Gross Margin | - | Volatility(W/M) | 0.13% 0.14% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.02 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.02 | EPS Q/Q | -18.01% | Profit Margin | - | RSI (14) | 77.18 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.02 | Sales Q/Q | - | SMA20 | 0.43% ($10.75) | Beta | 0.01 | Target Price | - |
| Payout | - | Debt/Eq | 0.01 | Earnings | - | SMA50 | 0.95% ($10.7) | Rel Volume | 0.02 | Prev Close | $10.8 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 2.78% ($10.51) | Avg Volume(3M) | 0.04M | Price | $10.8 |
| IPO | 2025/2/25 | Option/Short | No/Yes | Trades | 26 | Volume | 803 | Change | - |
Company
DMAA is a Financial sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 Drugs Made in America Acquisition (DMAA) is a blank check company (SPAC) that does not engage in direct operations. It is a special purpose acquisition company established for the purpose of raising funds through an IPO, placing them in a trust account, and finding a merger target within a set deadline to take it public through a reverse merger. The trust assets are invested in conservative short-term U.S. government bonds and similar instruments, and are preserved until the merger is completed or the company is liquidated.
Over the past 1 year, on the higher side
0% below its 1-year high.
DMAA has weak earning power
Tap to view numbers
But it is not cheap
Trading at 58.1 times earnings.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 49.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SPAQ 0.00%It ranks #4 in the industry
Based on market cap of $262M.
DMAA $262M PER 58.1
LION $3B PER -
BBCQ $2B PER -
CCXI $686M PER -
FAQ
What kind of company is DMAA?
DMAA belongs to the Financial sector and operates in the Shell Companies industry.
What is the market cap of DMAA?
The market cap of DMAA is approximately $262M, ranking 3,882 within its sector.
What is the P/E ratio of DMAA?
DMAA has a P/E ratio of approximately 58.1x, which can be used to assess its valuation relative to the Financial sector average.
What is the 52-week high and low for DMAA?
DMAA has recorded a 52-week high of $10.80 and a low of $10.23.
